Department of Head Neck Oncology, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Department of Radiation Oncology, Huanggang Central Hospital, Huanggang, 438000, China.
Curr Med Sci. 2021 Aug;41(4):737-745. doi: 10.1007/s11596-021-2405-3. Epub 2021 Aug 17.
To evaluate the long-term outcome and prognostic factors of patients with nasopharyngeal carcinoma (NPC) from low-endemic regions of China who received definitive intensity-modulated radiation therapy (IMRT).
The clinical data from 608 patients with newly-diagnosed non-metastatic NPC who have received initial treatment at our cancer center from January, 2008 to December, 2013 were retrospectively reviewed. All patients received definitive IMRT, and 87.7% received platinum-based chemotherapy.
The median follow-up duration was 51 months (follow-up rate, 98.5%; range, 10-106 months) for the entire cohort. The 5-year overall survival rate was 79.7%. The 5-year local relapse-free survival rate, regional relapse-free survival rate, distant metastasis-free survival rate and progression-free survival rate were 92.4%, 93.3%, 79.2% and 74.3%, respectively. A total of 153 patients had experienced treatment failure, with distant metastasis as the primary cause in 77.1% (118/153). Patients with T4 or N3 diseases had a significantly poorer prognosis than other subcategories. Stage T4 and N3 were closely associated with distant metastasis, with the metastatic rate of 29.3% and 45.5%, respectively.
IMRT provides patients with non-metastatic NPC with satisfactory long-term survival. Both T stage and N stage are important prognostic factors for NPC patients. Patients with T4 or N3 diseases have significantly increased distant metastatic rates and poor survival time.
评估中国低发地区接受根治性调强放疗(IMRT)的鼻咽癌(NPC)患者的长期预后和相关预后因素。
回顾性分析 2008 年 1 月至 2013 年 12 月在我院癌症中心接受初始治疗的 608 例初诊非转移性 NPC 患者的临床资料。所有患者均接受根治性 IMRT,87.7%的患者接受了铂类为基础的化疗。
全队列患者的中位随访时间为 51 个月(随访率 98.5%;范围 10-106 个月)。5 年总生存率为 79.7%。5 年局部无复发生存率、区域无复发生存率、无远处转移生存率和无进展生存率分别为 92.4%、93.3%、79.2%和 74.3%。共有 153 例患者发生治疗失败,其中远处转移是主要原因占 77.1%(118/153)。T4 或 N3 期患者的预后明显差于其他亚组。T4 期和 N3 期与远处转移密切相关,转移率分别为 29.3%和 45.5%。
IMRT 为非转移性 NPC 患者提供了令人满意的长期生存。T 分期和 N 分期均是 NPC 患者的重要预后因素。T4 或 N3 期患者远处转移率显著升高,生存时间较差。